SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3557 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2732Beats me! Expecting good 2Q!Miljenko Zuanic-7/22/2019
2731How much will the SP drop after earnings?Felix B-7/22/2019
2730Lucentis 2Q ex-US sale (from Novartis) were $536 m, more or less flat relative tMiljenko Zuanic-7/18/2019
2729Does short have a problem with ADVM? No at 13.5!Miljenko Zuanic-7/8/2019
2728Saga over REGN future continue, and Medicare(CMS) part B is major obstacle. ObviMiljenko Zuanic-7/6/2019
2727Due to its dermatology presence, and to *demoralized* Len self-fulfilling prophMiljenko Zuanic-7/2/2019
2726REGN3500 (anti IL-33 Ab) not as robust as Dupi in asthma control, also no robustMiljenko Zuanic-6/21/2019
2725Was I wrong on ADVM? Short interest triple in last few months? Who is wrong and Miljenko Zuanic-6/14/2019
2724Eylea PIGF cousin: finance.yahoo.comMiljenko Zuanic-6/7/2019
2723Gotcha, thanks for sharingFelix B-6/6/2019
27225678 is weekly iv, versus every 3 weeks for cemiplimab...so 3 times more frequenMiljenko Zuanic-6/4/2019
2721why not attractive? I am not familiar with oncologyFelix B-6/4/2019
2720Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Miljenko Zuanic-6/4/2019
2719A very interesting question and wondered that myself. 10 point scale--line drawkeokalani'nui-5/24/2019
2718How much mild-to-moderate AD overlap with moderate-to-severe AD?Miljenko Zuanic-5/24/2019
2717FWIW CARA response to Q whether korsuva might have a hard time in AD against bikeokalani'nui-5/23/2019
2716Today I sold my ADVM position. Sound to me that REGN is not much interested abouMiljenko Zuanic-5/20/2019
2715<I continue to be cautious optimistic with ADVM AAV program.> At this poiMiljenko Zuanic-5/17/2019
2714<New data at ASCO include more than double the patients previously reported; Miljenko Zuanic-5/16/2019
27131Q-2019 looks like *disaster*! Is't like that???? I continue to believe thaMiljenko Zuanic-5/8/2019
2712Thoughts on earnings?Felix B-5/7/2019
2711SNY 1Q: sanofi.com @e= 1.14$, Dupi US 1Q sale were $303m (ex-US = $72m), bit loMiljenko Zuanic-4/26/2019
2710Better to spend that profit on stronger Eylea future marketing, they will need iMiljenko Zuanic-4/25/2019
2709Eylea profits will enable Bayer to pay legal settlements and judgments for RoundDewDiligence_on_SI-4/25/2019
2708From Bayer 1Q results ( www.bayer.com/quarterly-release), Eylea ex-US sale are Miljenko Zuanic-4/25/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News